Image Guidance is Associated with Improved Freedom From Recurrence After Superficial Radiation Therapy for Nonmelanoma Skin Cancer

IF 2.2 Q3 ONCOLOGY

Advances in Radiation Oncology Pub Date : 2024-12-01 DOI:10.1016/j.adro.2024.101463

Erin M. McClure MD , Geoffrey Sedor MD , Mairead Moloney BS , Yuxuan Jin MS , Lio Yu MD , Michael W. Kattan PhD

{"title":"Image Guidance is Associated with Improved Freedom From Recurrence After Superficial Radiation Therapy for Nonmelanoma Skin Cancer","authors":"Erin M. McClure MD , Geoffrey Sedor MD , Mairead Moloney BS , Yuxuan Jin MS , Lio Yu MD , Michael W. Kattan PhD","doi":"10.1016/j.adro.2024.101463","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>This is the first study to quantify the 2-year freedom from recurrence for individuals with nonmelanoma skin cancer (NMSC) such as basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and squamous carcinoma in situ (SCCIS) treated with image guided superficial radiation therapy (IGSRT) versus SRT without image guidance.</div></div><div><h3>Methods and Materials</h3><div>This retrospective cohort study evaluates the 2-year freedom recurrence rate of NMSCs treated by IGSRT (March 2016 to January 2022) and compares it to existing data on NMSCs treated by SRT via 1 sample proportion tests. Individuals >18 years old with biopsy-proven SCC, SCCIS, and/or BCC treated with IGSRT were included in the study, and 1602 patients/2880 treated lesions were followed until January 14, 2022. SRT literature was identified through an Ovid Medline search.</div></div><div><h3>Results</h3><div>All NMSCs treated by IGSRT in this cohort had an aggregate 2-year freedom from recurrence of 99.23%. The recurrence rate for BCC (N = 1382) was 1.1%, for SCC (N = 904) 0.8%, and for SCCIS (N = 594) 0.0%. These recurrence rates are significantly improved compared with a pooled study that evaluated NMSCs across histology and BCCs alone treated without image guidance (standard SRT) (<em>P</em> < .001).</div></div><div><h3>Conclusions</h3><div>IGSRT offers a paradigm-shifting treatment option for patients with NMSCs – offering statistically significantly improved outcomes compared with standard SRT and a more desirable toxicity profile to surgical options. This study demonstrates that IGSRT is associated with remarkably low recurrence rates, which are statistically significantly improved from the previous generation of SRT and in line with modern outcomes for Mohs micrographic surgery.</div></div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"9 12","pages":"Article 101463"},"PeriodicalIF":2.2000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Radiation Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452109424000265","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

This is the first study to quantify the 2-year freedom from recurrence for individuals with nonmelanoma skin cancer (NMSC) such as basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and squamous carcinoma in situ (SCCIS) treated with image guided superficial radiation therapy (IGSRT) versus SRT without image guidance.

Methods and Materials

This retrospective cohort study evaluates the 2-year freedom recurrence rate of NMSCs treated by IGSRT (March 2016 to January 2022) and compares it to existing data on NMSCs treated by SRT via 1 sample proportion tests. Individuals >18 years old with biopsy-proven SCC, SCCIS, and/or BCC treated with IGSRT were included in the study, and 1602 patients/2880 treated lesions were followed until January 14, 2022. SRT literature was identified through an Ovid Medline search.

Results

All NMSCs treated by IGSRT in this cohort had an aggregate 2-year freedom from recurrence of 99.23%. The recurrence rate for BCC (N = 1382) was 1.1%, for SCC (N = 904) 0.8%, and for SCCIS (N = 594) 0.0%. These recurrence rates are significantly improved compared with a pooled study that evaluated NMSCs across histology and BCCs alone treated without image guidance (standard SRT) (P < .001).

Conclusions

IGSRT offers a paradigm-shifting treatment option for patients with NMSCs – offering statistically significantly improved outcomes compared with standard SRT and a more desirable toxicity profile to surgical options. This study demonstrates that IGSRT is associated with remarkably low recurrence rates, which are statistically significantly improved from the previous generation of SRT and in line with modern outcomes for Mohs micrographic surgery.

查看原文本刊更多论文

图像引导提高了非黑素瘤皮肤癌表层放疗后的复发率

目的：这是第一个量化非黑色素瘤皮肤癌（NMSC）患者(如基底细胞癌（BCC）、鳞状细胞癌（SCC）和原位鳞状癌（SCCIS）接受图像引导浅表放射治疗（IGSRT）与不进行图像引导的浅表放射治疗（SRT）的2年无复发的研究。方法和材料本回顾性队列研究评估了IGSRT治疗的NMSCs的2年自由复发率（2016年3月至2022年1月），并通过1样本比例检验将其与SRT治疗的NMSCs的现有数据进行比较。接受IGSRT治疗的18岁活检证实的SCC、SCCIS和/或BCC患者被纳入研究，1602例患者/2880例治疗病变被随访至2022年1月14日。通过Ovid Medline检索确定SRT文献。结果在该队列中，所有接受IGSRT治疗的NMSCs的2年总复发率为99.23%。BCC （N = 1382）复发率为1.1%,SCC （N = 904）为0.8%,SCCIS （N = 594）为0.0%。与一项综合研究相比，这些复发率显着提高，该研究评估了组织学上的NMSCs和单独治疗的bcc，没有图像引导（标准SRT） (P <；措施)。结论：与标准SRT相比，sigsrt为NMSCs患者提供了一种范式转换的治疗选择，在统计学上显著改善了结果，并且比手术选择具有更理想的毒性。本研究表明，IGSRT的复发率非常低，与上一代SRT相比有统计学上的显著改善，与Mohs显微摄影手术的现代结果一致。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Radiation Oncology Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

4.60

自引率

4.30%

发文量

208

审稿时长

98 days

期刊介绍： The purpose of Advances is to provide information for clinicians who use radiation therapy by publishing: Clinical trial reports and reanalyses. Basic science original reports. Manuscripts examining health services research, comparative and cost effectiveness research, and systematic reviews. Case reports documenting unusual problems and solutions. High quality multi and single institutional series, as well as other novel retrospective hypothesis generating series. Timely critical reviews on important topics in radiation oncology, such as side effects. Articles reporting the natural history of disease and patterns of failure, particularly as they relate to treatment volume delineation. Articles on safety and quality in radiation therapy. Essays on clinical experience. Articles on practice transformation in radiation oncology, in particular: Aspects of health policy that may impact the future practice of radiation oncology. How information technology, such as data analytics and systems innovations, will change radiation oncology practice. Articles on imaging as they relate to radiation therapy treatment.